Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.
Clinical trial NCT07121322 · RECRUITING
Trial details
- NCT number
- NCT07121322
- Sponsor
- National Cancer Institute, Slovakia
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-30
- Primary completion
- 2027-07-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.